North Central Cancer Treatment Group

• NCT00929591

  Collaborator, Phase 3, Completed, 1,558 people, 29 Jun 2009

• NCT00754845

  Collaborator, Phase 3, Completed, 1,918 people, 18 Sept 2008

• NCT00533949

  Collaborator, Phase 3, Completed, 544 people, 24 Sept 2007

• NCT00499369

  Collaborator, Phase 3, Terminated, 72 people, 11 Jul 2007

• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

  Collaborator, Phase 3, Active, not recruiting, 4,994 people, 12 Feb 2007

• NCT00354302

  Collaborator, Phase 3, Completed, 497 people, 20 Jul 2006

• NCT00324805

  Collaborator, Phase 3, Completed, 1,501 people, 11 May 2006

• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

  Collaborator, Phase 3, Active, not recruiting, 10,273 people, 3 Apr 2006

• NCT00127205

  Collaborator, Phase 3, Completed, 6,097 people, 5 Aug 2005

• NCT00113386

  Collaborator, Phase 3, Terminated, 19 people, 8 Jun 2005

• NCT00101283

  Collaborator, Phase 2, Completed, 32 people, 10 Jan 2005

• NCT00002872

  Collaborator, Phase 3, Completed, 480 people, 2 Sept 2004

• NCT00002593

  Collaborator, Phase 3, Completed, 1,135 people, 31 Aug 2004

• NCT00002570

  Collaborator, Phase 3, Completed, 67 people, 31 Aug 2004

• NCT00002631

  Collaborator, Phase 3, Completed, 298 people, 31 Aug 2004

• NCT00003519

  Collaborator, Phase 3, Completed, 2,778 people, 26 Aug 2004

• NCT00002642

  Collaborator, Phase 2, Completed, 116 people, 30 Jun 2004

• NCT00002646

  Collaborator, Phase 3, Completed, 1,500 people, 10 Jun 2004

• NCT00002551

  Collaborator, Phase 3, Completed, 1,917 people, 10 Jun 2004

• NCT00003835

  Collaborator, Phase 3, Completed, 1,260 people, 27 Apr 2004

Sources: clinicaltrials.gov